{"url_path":"/sec/engn/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270386-index.html","accession_number":"0001193125-26-270386","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270386-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":55,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nInsider Adoption or Termination of Trading Arrangements. \n\nDuring the fiscal quarter ended April 30, 2026, none of our directors or officers informed us of the adoption or termination of a \"Rule 10b5-1 trading arrangement\" or \"non-Rule 10b5-1 trading arrangement\" (as each term is defined in Item 408(a) of Regulation S-K).\n\n37"}